Friedreich’s Ataxia

March 9, 2015March 9, 2015

Reata Announces Enrollment of First Patient in Phase 2 Study of RTA 408 for the Treatment of Friedreich’s Ataxia

Irving, Texas based Reata Pharmaceuticals, whose mission is to translate innovative research into breakthrough medicines for difficult-to-treat diseases that have significant unmet needs, recently announced the enrollment of their first patient ... Read more

February 24, 2015February 24, 2015

Novel Therapy for Multiple Mitochondrial Diseases Now in Clinical Trials

Friedreich's Ataxia, Kearns-Sayre syndrome, Leigh syndrome

Edison Pharmaceuticals is actively engaged in a number of phase 2 clinical trials investigating their drug candidate EPI-743 in a variety of mitochondrial respiratory chain diseases. The studies range from ... Read more